CORDY

Corporate Overview

  1. Top
  2. Business area
  3. Corporate Overview
Company name
Perseus Proteomics Inc.
Office
Headquarters
4-7-6, Komaba Meguro-ku, Tokyo 153-0041, JAPAN
Nagoya Laboratory
302・303・306, Nagoya Life Science Incubator
2-22-8 Chikusa, Chikusa-ku, Nagoya, Aichi 464-0858, JAPAN
Established
February 1, 2001
Capital
1,939 million Yen (as of September 30, 2021)
Number of employees
22 (as of June 22, 2021)
Board of Directors
President & CEO Takuya Yokokawa
Director
Shinichi Suzukawa (General Manager, Administrative Division)
Tadashi Matsuura (General Manager, Research and Development Division)
Kinichiro Kominami (Tech & FinStrategy, Inc. President & CEO)
Toshikazu Ban
Nobuo Hanai (SHIMADZU CORPORATION, Outside Director)
Director,
Audit & Supervisory Committee Member
Kazuo Miwa
Tadashi Horiuchi, Guest Professor, Ph.D. (Keio University Hospital)
Takashi Ohno, certified public accountant (Ohno Certified Public Accountant Office)

Corporate History

February 2001
Perseus Proteomics is established in Bunkyo-ku, Tokyo.
October 2002
A number of anti-nuclear receptor monoclonal antibodies are released as research reagents.
April 2003
The company joins the “Protein Interaction Analysis Nano-biochip Project” sponsored by the New Energy and Industrial Technology Development Organization (NEDO) of the Ministry of Economy, Trade and Industry.
July 2003
The company headquarters relocate to Shibuya-ku, Tokyo.
August 2004
The company signs a distributorship agreement with R&D Systems Inc. for the distribution of its research reagents in the United States and initiates global sales.
September 2004
The company headquarters relocate to Meguro-ku, Tokyo.
September 2005
The complete lineup of antibodies that target all 48 nuclear receptors is presented.
September 2006
The company signs an agreement with Chugai Pharmaceutical Co., Ltd. for the transfer of right for the therapeutic use of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001).”
September 2008
The research reagent “PTX3 ELISA kit” is released.
November 2008
A phase I clinical trial of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001)” begins in the United States.
January 2009
Through shareholder allocation, FUJIFILM Corporation increase their capital in Perseus Proteomics by acquiring 76.68% of the issued shares to become the parent company.
January 2011
A radioisotope (RI)-labeled antibody (PPMX-T002), an anticancer drug, is licensed to FUJIFILM Corporation.
December 2014
A drug for the treatment of adult T-cell leukemia based on an anti-transferrin receptor antibody (PPMX-T003) is selected by the Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) program of the Japan Science and Technology Agency (JST) for the practical application development (drug development) division.
September 2015
Antibody Drug Conjugate (PPMX-T004) is licensed to FUJIFILM Corporation.
January 2016
A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in the United States.
March 2018
After allocation of new shares to a third party, FUJIFILM Corporation reduce their percentage of shares to 48.62% and become an affiliated company.
January 2019
The company opens the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, for the maintenance and development of phage display technologies and the promotion of research and development of antibody drugs.
November 2019
A phase I clinical trial of the anti-transferrin receptor antibody (PPMX-T003) as an anticancer drug begins in Japan.
April 2020
A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in Japan.